TY - JOUR
T1 - Progress Toward Measles Elimination — Worldwide, 2000–2022
AU - Minta, Anna A.
AU - Ferrari, Matt
AU - Antoni, Sebastien
AU - Portnoy, Allison
AU - Sbarra, Alyssa
AU - Lambert, Brian
AU - Hatcher, Cynthia
AU - Hsu, Christopher H.
AU - Ho, Lee Lee
AU - Steulet, Claudia
AU - Gacic-Dobo, Marta
AU - Rota, Paul A.
AU - Mulders, Mick N.
AU - Bose, Anindya Sekhar
AU - Caro, William Perea
AU - O’Connor, Patrick
AU - Crowcroft, Natasha S.
N1 - Publisher Copyright:
© (2023), (Centers for Disease Control and Prevention (CDC)). All Rights Reserved.
PY - 2023
Y1 - 2023
N2 - Measles is a highly contagious, vaccine-preventable disease that requires high population immunity for transmission to be interrupted. All six World Health Organization regions have committed to eliminating measles; however, no region has achieved and sustained measles elimination. This report describes measles elimination progress during 2000–2022. During 2000–2019, estimated coverage worldwide with the first dose of measles-containing vaccine (MCV) increased from 72% to 86%, then declined to 81% in 2021 during the COVID-19 pandemic, representing the lowest coverage since 2008. In 2022, first-dose MCV coverage increased to 83%. Only one half (72) of 144 countries reporting measles cases achieved the measles surveillance indicator target of two or more discarded cases per 100,000 population in 2022. During 2021–2022, estimated measles cases increased 18%, from 7,802,000 to 9,232,300, and the number of countries experiencing large or disruptive outbreaks increased from 22 to 37. Estimated measles deaths increased 43% during 2021–2022, from 95,000 to 136,200. Nonetheless, an estimated 57 million measles deaths were averted by vaccination during 2000–2022. In 2022, measles vaccination coverage and global surveillance showed some recovery from the COVID-19 pandemic setbacks; however, coverage declined in low-income countries, and globally, years of suboptimal immunization coverage left millions of children unprotected. Urgent reversal of coverage setbacks experienced during the COVID-19 pandemic can be accomplished by renewing efforts to vaccinate all children with 2 MCV doses and strengthening surveillance, thereby preventing outbreaks and accelerating progress toward measles elimination.
AB - Measles is a highly contagious, vaccine-preventable disease that requires high population immunity for transmission to be interrupted. All six World Health Organization regions have committed to eliminating measles; however, no region has achieved and sustained measles elimination. This report describes measles elimination progress during 2000–2022. During 2000–2019, estimated coverage worldwide with the first dose of measles-containing vaccine (MCV) increased from 72% to 86%, then declined to 81% in 2021 during the COVID-19 pandemic, representing the lowest coverage since 2008. In 2022, first-dose MCV coverage increased to 83%. Only one half (72) of 144 countries reporting measles cases achieved the measles surveillance indicator target of two or more discarded cases per 100,000 population in 2022. During 2021–2022, estimated measles cases increased 18%, from 7,802,000 to 9,232,300, and the number of countries experiencing large or disruptive outbreaks increased from 22 to 37. Estimated measles deaths increased 43% during 2021–2022, from 95,000 to 136,200. Nonetheless, an estimated 57 million measles deaths were averted by vaccination during 2000–2022. In 2022, measles vaccination coverage and global surveillance showed some recovery from the COVID-19 pandemic setbacks; however, coverage declined in low-income countries, and globally, years of suboptimal immunization coverage left millions of children unprotected. Urgent reversal of coverage setbacks experienced during the COVID-19 pandemic can be accomplished by renewing efforts to vaccinate all children with 2 MCV doses and strengthening surveillance, thereby preventing outbreaks and accelerating progress toward measles elimination.
UR - http://www.scopus.com/inward/record.url?scp=85177468754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85177468754&partnerID=8YFLogxK
U2 - 10.15585/mmwr.mm7246a3
DO - 10.15585/mmwr.mm7246a3
M3 - Article
C2 - 37971951
AN - SCOPUS:85177468754
SN - 0149-2195
VL - 72
SP - 1262
EP - 1268
JO - Morbidity and Mortality Weekly Report
JF - Morbidity and Mortality Weekly Report
IS - 46
ER -